Peripheral neuropathy in children and adolescents treated for cancer

Kari L. Bjornard, Laura S. Gilchrist, Hiroto Inaba, Barthelemy Diouf, Marilyn J. Hockenberry, Nina S. Kadan-Lottick, Daniel C. Bowers, M. Eileen Dolan, Nicole J. Ullrich, William E. Evans, Kirsten K. Ness

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer, associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in sensory, motor, or autonomic neurons, with symptoms that are rarely life threatening, but often severe enough to interfere with function during therapy and after treatment ends. The type of neuropathy and specific symptoms are associated with multiple factors including age at time of therapy, genetic predisposition, chemotherapy type and cumulative dose, and exposure to other agents during therapy. In this Review, we describe the peripheral neuropathy phenotype in children during cancer therapy and among survivors who have completed therapy, to summarise genetic and treatment-related risk factors for neuropathy, and to outline strategies to monitor and detect neuropathy during and after therapy. Additionally, we outline strategies for medical management of neuropathy during treatment and potential rehabilitation interventions to prevent or remediate functional loss.

Original languageEnglish (US)
Pages (from-to)744-754
Number of pages11
JournalThe Lancet Child and Adolescent Health
Volume2
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Peripheral Nervous System Diseases
Neoplasms
Therapeutics
Drug Therapy
Age Factors
Genetic Predisposition to Disease
Rehabilitation
Phenotype
Neurons

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology

Cite this

Bjornard, K. L., Gilchrist, L. S., Inaba, H., Diouf, B., Hockenberry, M. J., Kadan-Lottick, N. S., ... Ness, K. K. (2018). Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child and Adolescent Health, 2(10), 744-754. https://doi.org/10.1016/S2352-4642(18)30236-0

Peripheral neuropathy in children and adolescents treated for cancer. / Bjornard, Kari L.; Gilchrist, Laura S.; Inaba, Hiroto; Diouf, Barthelemy; Hockenberry, Marilyn J.; Kadan-Lottick, Nina S.; Bowers, Daniel C.; Dolan, M. Eileen; Ullrich, Nicole J.; Evans, William E.; Ness, Kirsten K.

In: The Lancet Child and Adolescent Health, Vol. 2, No. 10, 01.10.2018, p. 744-754.

Research output: Contribution to journalReview article

Bjornard, KL, Gilchrist, LS, Inaba, H, Diouf, B, Hockenberry, MJ, Kadan-Lottick, NS, Bowers, DC, Dolan, ME, Ullrich, NJ, Evans, WE & Ness, KK 2018, 'Peripheral neuropathy in children and adolescents treated for cancer', The Lancet Child and Adolescent Health, vol. 2, no. 10, pp. 744-754. https://doi.org/10.1016/S2352-4642(18)30236-0
Bjornard KL, Gilchrist LS, Inaba H, Diouf B, Hockenberry MJ, Kadan-Lottick NS et al. Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child and Adolescent Health. 2018 Oct 1;2(10):744-754. https://doi.org/10.1016/S2352-4642(18)30236-0
Bjornard, Kari L. ; Gilchrist, Laura S. ; Inaba, Hiroto ; Diouf, Barthelemy ; Hockenberry, Marilyn J. ; Kadan-Lottick, Nina S. ; Bowers, Daniel C. ; Dolan, M. Eileen ; Ullrich, Nicole J. ; Evans, William E. ; Ness, Kirsten K. / Peripheral neuropathy in children and adolescents treated for cancer. In: The Lancet Child and Adolescent Health. 2018 ; Vol. 2, No. 10. pp. 744-754.
@article{fee25125bd5e485b82e6a4fc82a9be5b,
title = "Peripheral neuropathy in children and adolescents treated for cancer",
abstract = "Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer, associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in sensory, motor, or autonomic neurons, with symptoms that are rarely life threatening, but often severe enough to interfere with function during therapy and after treatment ends. The type of neuropathy and specific symptoms are associated with multiple factors including age at time of therapy, genetic predisposition, chemotherapy type and cumulative dose, and exposure to other agents during therapy. In this Review, we describe the peripheral neuropathy phenotype in children during cancer therapy and among survivors who have completed therapy, to summarise genetic and treatment-related risk factors for neuropathy, and to outline strategies to monitor and detect neuropathy during and after therapy. Additionally, we outline strategies for medical management of neuropathy during treatment and potential rehabilitation interventions to prevent or remediate functional loss.",
author = "Bjornard, {Kari L.} and Gilchrist, {Laura S.} and Hiroto Inaba and Barthelemy Diouf and Hockenberry, {Marilyn J.} and Kadan-Lottick, {Nina S.} and Bowers, {Daniel C.} and Dolan, {M. Eileen} and Ullrich, {Nicole J.} and Evans, {William E.} and Ness, {Kirsten K.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/S2352-4642(18)30236-0",
language = "English (US)",
volume = "2",
pages = "744--754",
journal = "The Lancet Child and Adolescent Health",
issn = "2352-4642",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Peripheral neuropathy in children and adolescents treated for cancer

AU - Bjornard, Kari L.

AU - Gilchrist, Laura S.

AU - Inaba, Hiroto

AU - Diouf, Barthelemy

AU - Hockenberry, Marilyn J.

AU - Kadan-Lottick, Nina S.

AU - Bowers, Daniel C.

AU - Dolan, M. Eileen

AU - Ullrich, Nicole J.

AU - Evans, William E.

AU - Ness, Kirsten K.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer, associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in sensory, motor, or autonomic neurons, with symptoms that are rarely life threatening, but often severe enough to interfere with function during therapy and after treatment ends. The type of neuropathy and specific symptoms are associated with multiple factors including age at time of therapy, genetic predisposition, chemotherapy type and cumulative dose, and exposure to other agents during therapy. In this Review, we describe the peripheral neuropathy phenotype in children during cancer therapy and among survivors who have completed therapy, to summarise genetic and treatment-related risk factors for neuropathy, and to outline strategies to monitor and detect neuropathy during and after therapy. Additionally, we outline strategies for medical management of neuropathy during treatment and potential rehabilitation interventions to prevent or remediate functional loss.

AB - Peripheral neuropathy is a well recognised treatment-related toxicity in children with cancer, associated with exposure to neurotoxic chemotherapy agents. Acute damage can occur in sensory, motor, or autonomic neurons, with symptoms that are rarely life threatening, but often severe enough to interfere with function during therapy and after treatment ends. The type of neuropathy and specific symptoms are associated with multiple factors including age at time of therapy, genetic predisposition, chemotherapy type and cumulative dose, and exposure to other agents during therapy. In this Review, we describe the peripheral neuropathy phenotype in children during cancer therapy and among survivors who have completed therapy, to summarise genetic and treatment-related risk factors for neuropathy, and to outline strategies to monitor and detect neuropathy during and after therapy. Additionally, we outline strategies for medical management of neuropathy during treatment and potential rehabilitation interventions to prevent or remediate functional loss.

UR - http://www.scopus.com/inward/record.url?scp=85054861074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054861074&partnerID=8YFLogxK

U2 - 10.1016/S2352-4642(18)30236-0

DO - 10.1016/S2352-4642(18)30236-0

M3 - Review article

C2 - 30236383

AN - SCOPUS:85054861074

VL - 2

SP - 744

EP - 754

JO - The Lancet Child and Adolescent Health

JF - The Lancet Child and Adolescent Health

SN - 2352-4642

IS - 10

ER -